Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Dividend Yield on January 14, 2025: 0.38%

Jiangsu Hengrui Medicine Co., Ltd. Dividend Yield is 0.38% on January 14, 2025, a -0.26% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Jiangsu Hengrui Medicine Co., Ltd. 52-week high Dividend Yield is 0.44% on February 02, 2024, which is 16.14% above the current Dividend Yield.
Jiangsu Hengrui Medicine Co., Ltd. 52-week low Dividend Yield is 0.28% on October 08, 2024, which is -24.87% below the current Dividend Yield.
Jiangsu Hengrui Medicine Co., Ltd. average Dividend Yield for the last 52 weeks is 0.36%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years